Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
- Sprache
-
Englisch
- Umfang
-
Online-Ressource
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Erschienen in
-
In: The prostate, 82.2022, 6, S. 676-686
- Urheber
-
Höh, Robert Benedikt
Würnschimmel, Christoph
Flammia, Rocco Simone
Horlemann, Benedikt
Sorce, Gabriele
Chierigo, Francesco
Tian, Zhe
Saad, Fred
Graefen, Markus
Gallucci, Michele
Briganti, Alberto
Terrone, Carlo
Shariat, Shahrokh F.
Tilki, Derya
Kluth, Luis
Mandel, Philipp
Chun, Felix
Karakiewicz, Pierre I.
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2022
- DOI
-
10.1002/pros.24312
- URN
-
urn:nbn:de:hebis:30:3-754371
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:53 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Höh, Robert Benedikt
- Würnschimmel, Christoph
- Flammia, Rocco Simone
- Horlemann, Benedikt
- Sorce, Gabriele
- Chierigo, Francesco
- Tian, Zhe
- Saad, Fred
- Graefen, Markus
- Gallucci, Michele
- Briganti, Alberto
- Terrone, Carlo
- Shariat, Shahrokh F.
- Tilki, Derya
- Kluth, Luis
- Mandel, Philipp
- Chun, Felix
- Karakiewicz, Pierre I.
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2022
Ähnliche Objekte (12)
Effect of chemotherapy on overall survival in contemporary metastatic prostate cancer patients
Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Diabetes and beta adrenergic blockage are risk factors for metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Mechanism of cancer evading metronomic chemotherapy and action of archazolid as an anti-metastatic drug
Commentary: Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor
Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug
Effect of chemotherapy on overall survival in contemporary metastatic prostate cancer patients
Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Diabetes and beta adrenergic blockage are risk factors for metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Mechanism of cancer evading metronomic chemotherapy and action of archazolid as an anti-metastatic drug
Commentary: Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor
Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug
Effect of chemotherapy on overall survival in contemporary metastatic prostate cancer patients
Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Diabetes and beta adrenergic blockage are risk factors for metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Mechanism of cancer evading metronomic chemotherapy and action of archazolid as an anti-metastatic drug
Commentary: Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor